A lateral flow test is a type of assay that is also referred to as a quick test, lateral flow device, or lateral flow immunochromatographic assay. It is a straightforward tool design to identify a target material in a particular liquid sample without using any complex or expensive equipment. The majority of LFA studies identify IgG & IgM antibodies separately. When compared to a singular IgG or IgM test, the IgM-IgG combination assay is more useful and sensitive. Li et al. published the first LFA-based investigation for the early detection process of SARS-CoV-2 in 2020.

 

The Lateral Flow Assays Market’s worth was $ 8.77 Bn in 2021 & will value at $ 12.86 Bn by 2030, with a 4.32% CAGR.

 

A quick test called the Wondfo Antigen Test (LFA/Lateral Flow Method) was employed to identify the N protein antigen of novel coronaviruses (2019-nCoV) that was recovered from a nasal swab specimen. It is designed to help symptomatic patients diagnose 2019-nCoV-caused coronavirus disease (COVID-19) within seven days of the onset of symptoms.

 

Lateral Flow Assays Market, future prospects, key trends, growth rate, as well as some related statistics.

 

• The frequency of infectious diseases remains high on a worldwide scale despite significant breakthroughs in medicine and sanitation. Infectious diseases continue to be a significant public health issue globally, despite the fact that non-communicable diseases account for the majority of morbidity and mortality. According to a study by the NIA and Infectious Diseases, over 15 million people die from infectious diseases each year around the world. It is anticipated that the use of LFA/ lateral flow assay testing will rise in underdeveloped countries because of the high prevalence of communicable diseases like HIV and malaria, insufficient healthcare infrastructure, and growing public awareness.

 

    By Type

 

• Age-related changes, as well as metabolic issues, frequently contribute to the rise of chronic diseases such as cystic fibrosis, cardiovascular disease, hepatitis, and cancer. Geriatric adults have weak immune systems, making them more susceptible to illnesses and infections. The lateral flow tests market is expanding significantly due in large part to the global increase in the senior population and the growing patient pool for chronic disorders.

 

• The majority of diagnostic procedures performed now around the globe take place in laboratories. On the other hand, there is a rising need for POC diagnostics for LFA tests to replace time-consuming and conventional laboratory procedures. POC diagnostic tests also have lower costs than traditional laboratory diagnostic techniques since they require less complex infrastructure and training. Point-of-care testing is anticipate to hold the maximum share in the field of lateral flow assays because of its importance in reducing the burden of disease, which is on the rise.

 

    By Application

 

• The lateral flow assay has significantly changed over the past 20 years. It is currently frequently used in diagnostic and point-of-care applications. The production of lateral flow assays can make use of capillary flow and nitrocellulose membrane. Point-of-care (POC), pregnancy testing, and the detection of infectious diseases all use the lateral flow assay. There are lateral flow assay instruments for antibodies, membrane, medicinal, veterinary, food, and agricultural use on the market. The analysis of the flow cytometry sector has made these devices vital. Electrochemical lateral flow test, fluorescence lateral flow assay, sers-based lateral flow assay, photothermal LFA, immuno-chromatographic assay, biosensors, photothermal lateral flow assay, POC diagnostics, polymerase chain reaction, ELISA, quantitative lateral flow assay, & magnetic lateral flow Immunoassay can contribute to a beneficial change in market patterns in the future, allowing for numerous prospects for growth.

 

 

Segments inculcated:-

 

Product

• Lateral Flow Readers
• Kits & Reagents

 

Application

• Cardiac Marker Testing
• Clinical Testing
• Drugs of Abuse Testing
• LPT/Lipid Profile Testing
• Pregnancy and Fertility Testing
• Others

 

Technique

• Competitive Assay
• Sandwich Assay
• Multiplex Detection Assay

 

End-Use

• Diagnostic Laboratories
• Hospitals and Clinics
• Pharma and Bio Companies
• Homecare
• Others

 

Players involved:

• Quidel Corporation
• Abbott Laboratories
• Danaher Corporation
• F. Hoffman-La Roche AG
• Siemens AG
• bioMérieux SA
• Becton, Dickinson and Company
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories
• Hologic Inc.
• PerkinElmer Inc.
• Merck KGaA
• QIAGEN N.V.

 

 

Recent Development

• In 2022, Becton, Dickinson, and Company was given the authorization to use the Scan well Health-Mobile App for the OTC rapid antigen test. This short, digitally readable LF antigen self-test was develope by B.D. to make COVID-19 testing quicker and safer for consumers to undertake at home.

 

• In 2021, a new production facility in Buchs was expand by Merck KGaA for USD 21 million. Researchers in LFA testing labs throughout the world use Merck’s reference materials in this facility on a regular basis to help them produce reliable, dependable analytical findings for environmental, pharmaceutical, as well as food, and beverage analysis.